ASB-17 Activators
The chemical class of ASB17 activators includes a range of compounds that indirectly influence the activity of ASB17, primarily through modulation of protein ubiquitination, degradation pathways, and cellular signaling. This group comprises various proteasome inhibitors like MG132, Bortezomib, Lactacystin, Velcade, and Epoxomicin. By impacting the ubiquitin-proteasome system, these inhibitors could alter the protein degradation pathways where ASB17 may be involved, thereby potentially influencing its function in ubiquitination processes.
Additionally, this class may encompass compounds that affect specific aspects of ubiquitination and protein stability, such as MLN4924, PYR-41, and IU1. These compounds, by targeting ubiquitin activation, neddylation processes, and deubiquitination mechanisms, respectively, offer indirect routes to modulate ASB17 activity. Furthermore, compounds like Nutlin-3 and Thalidomide, which influence ubiquitin ligase activity, and 17-AAG, an Hsp90 inhibitor, also contribute to this class by affecting protein stability and degradation pathways. Moreover, Chloroquine, an autophagy inhibitor, highlights the interconnected nature of cellular degradation pathways, including both the ubiquitin-proteasome system and autophagic processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor; can indirectly influence ASB17 by altering ubiquitin-proteasome system, potentially affecting protein degradation pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor; might modulate ASB17 activity indirectly through its impact on the ubiquitin-proteasome pathway. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
A proteasome inhibitor; potentially influences ASB17 by altering proteasomal degradation pathways. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor; might influence ASB17 indirectly through its effects on proteasomal degradation mechanisms. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits the NEDD8-activating enzyme; might indirectly affect ASB17 through modulation of neddylation and ubiquitination processes. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
A ubiquitin-activating enzyme E1 inhibitor; can affect ASB17 indirectly by modulating ubiquitination processes. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
An inhibitor of USP14, a proteasome-associated deubiquitinase; can indirectly affect ASB17 by modulating deubiquitination processes. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Disrupts MDM2-p53 interaction; might modulate ASB17 activity indirectly by affecting ubiquitin-mediated degradation pathways. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates E3 ubiquitin ligase activity; potentially affects ASB17 indirectly by influencing ubiquitin ligase-mediated protein degradation. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Inhibits autophagy; can indirectly influence ASB17 by modulating autophagic degradation pathways, which intersect with ubiquitination processes. | ||||||